Monday 1st December – Day 1 Main Conference - GMT (Greenwich Mean Time, GMTZ)
- Catherine Simpson - Conference Director - Cell and Gene Therapy Portfolio, Informa Connect LifeSciences
- Marion Hitchcock - Managing Director Gene & Cell Therapies Incubator Berlin, Bayer
Starting from a brownfield and a greenfield, 2 brand new facilities for CAR-T production were built in Ghent in 2-3 years’ time. Building up the facility, recruiting and training people, building and qualifying processes and systems, passing HA inspections, meeting customer’s needs, an amazing experience for all involved.
- Frederik Buysse - VP-General Manager EU, Legend Biotech
- Snapshot into the investment landscape for CGT products and enabling technologies: Our expert investors reveal their bold predictions for CGT's trajectory through 2026
- Uncover game-changing investment opportunities in CGT as leading investors reveal which technologies are poised to disrupt healthcare and deliver exceptional returns
- Standing out in the crowd: Positioning for success in a competitive funding environment: What do investors need to see?
“Ask the Investor” interactive Q&A open discussion with our investor panel to get tips and tricks when pitching and their views on where innovation lies in the CGT field
- Bo Wiinberg - Chief Business Development Officer, Novo Nordisk Foundation Cellerator
- Matthieu Coutet - Partner, Sofinnova Partners
- Therese Liechtenstein - Investment Director, 4BIO Capital
- Hakan Goker - Managing Director, M Ventures
- Ole Henrik Bang-Andreasen - Principal, Avant Bio
- Artemy Shumskiy - Senior Associate, LongeVC
- Stijn Heessen - Co-founder, COO, Alder Therapeutics AB
- Jan Spanholtz - CSO, Glycostem Therapeutics
- Anette Brass - Head of Process Development, Anocca
- Larry Forman - Founder and CEO, CHO Plus, Inc.
- Giovanni Ganendra - Upstream Process Science Senior Scientist, UCB
The CGT C-Level Forum provides a unique, powerful and valuable space for candidly sharing ideas and experiences between executives of ~20 CGT therapeutic development companies. The forum is designed to foster new ideas and create new relationships between attendees so that they can leave with tangible outcomes and that will drive their businesses and the sector forward.
An exclusive invite-only session, in a closed room setting, the forum will include 2-3 case studies discussing the right approach to engage and partner with pharma and industry. It will also include general discussion focussed on brainstorming solutions to the most pressing and current challenges of CEO/CSO/CBO/CMOs in the CGT sector.
Visit KyooBe during the Live Lab tour and explore our innovative cube-based production approach for cell and gene therapies. Our cubes are mobile aseptic units that integrate seamlessly with isolators for safe, segregated batch production. Experience how closed modular design and automation bring flexibility, safety, and efficiency to personalized medicine.
- Andrea Gaißler - Research Associate, Fraunhofer Institute for Manufacturing Engineering and Automation IPA
- Lindsay Davies - Chief Scientific Officer, NextCell Pharma
- Olivia Candini - Head of Process Development, Cell & Gene Therapy, Evotec Modena
- Julie Aubert - DSP Development Engineer, Généthon
- Mirjana Cvijanovic - Scientific Sr. Manager, Johnson & Johnson
- Dethardt Müeller - Chief Technology Officer - CMC, Abalos Therapeutics GmbH
- Lucas Arruda - Chief Scientific Officer, CuraCell
- Gonzalo Fernández-Miranda - CEO and Co-Founder, CureAge Therapeutics
- Regine Heilbronn - Co-Founder and CEO, EpiBlok Therapeutics
- Ángel Lucio Pereira - Chief Executive Officer, Tetraneuron
- Tamás Kitka - Founder, Managing Director, CREATe Therapeutics
- Marina Tarunina - Research Director, Plasticell Ltd
- Eric Halioua - President & Chief Executive Officer, PDC*line Pharma
- Markus Haindl - Global Head Gene Therapy Technical Research & Development, Roche-Genentech